Mar 07, 2023 / 05:50PM GMT
Unidentified Analyst
Panel is the GI/GU Oncology Panel. And with us we have six companies. I'm just going to introduce them one by one in alphabetical order. We have Daniel O'Connor from Ambrx; we have Mark Erlander from Cardiff; we have Joe Ferra from Elevation Oncology; we have Scott Koenig from MacroGenics; Joe McCann from POINT Biopharma; and Liz Barrett from UroGen. I thank everybody for joining us.
Questions and Answers:
Unidentified AnalystIn terms of the format, we're going to ask only two general questions to the panelists. And then we're going to go round with specific company focused questions. So first question is in GI/GU Oncology includes obviously a wide range of tumor types, each of which has unique development considerations. However, there are some regulatory factors that broadly apply to all these tumors. And I'll start with project documents. Are you incorporating that in your clinical development?
So maybe let's just start with, I guess the left side of the table (multiple speakers).
Daniel O'Connor
Trustpilot
